Prolia (Denosumab) for Giant Cell Tumor: Off-Label Dosing, Evidence, and Clinical Protocol

What Denosumab Actually Is and Why Formulation Matters

Denosumab is a fully human monoclonal antibody that targets RANK ligand (RANKL), a cytokine that drives osteoclast formation and activation. By blocking RANKL, denosumab prevents the osteoclast-mediated bone destruction that underpins conditions from postmenopausal osteoporosis to bone metastases. FDA prescribing information for both formulations is distinct.

Xgeva versus Prolia: Not the Same Drug in Practice

Two separate FDA-approved products carry the denosumab molecule:

• Prolia (60 mg / 1 mL prefilled syringe): Approved for postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and bone loss from hormone-ablation therapy. Dosing is 60 mg SC every 6 months.
• Xgeva (120 mg / 1.7 mL vial): Approved for prevention of skeletal-related events in multiple myeloma and solid tumors with bone metastases, and specifically for giant cell tumor of bone in adults and skeletally mature adolescents who are unresectable, recurrent, or where surgery would result in severe morbidity. Dosing is 120 mg SC every 4 weeks. Full Xgeva prescribing information is available via FDA.

The 60 mg Prolia dose used every 6 months for osteoporosis does not achieve the exposure needed for GCTB tumor control. Prescribing Prolia instead of Xgeva for a GCTB patient would be an off-label use of the wrong formulation at the wrong dose and interval.

FDA Approval Timeline for GCTB

The FDA granted Xgeva approval for GCTB in June 2013, based on the Phase II open-label study sponsored by Amgen. That approval was the first systemic therapy specifically indicated for this tumor type, which had previously been managed almost entirely through surgery. The original FDA approval summary is indexed at FDA.gov.

Giant Cell Tumor of Bone: Biology and Why RANKL Matters

Giant cell tumor of bone is a locally aggressive primary bone tumor accounting for roughly 5% of all primary bone tumors and 20% of benign bone tumors in some series. It most commonly affects the epiphysis of long bones in skeletally mature adults aged 20 to 40 years. Despite its benign histological classification in most cases, GCTB can recur locally in 15% to 50% of cases after curettage, and approximately 1% to 3% of cases undergo malignant transformation. Epidemiology and pathology are reviewed in this NCBI resource.

The RANKL Mechanism in GCTB

The stromal cells in GCTB express high levels of RANKL. Those stromal cells recruit RANK-expressing osteoclast precursors, which differentiate into the multinucleated giant cells that give the tumor its name. These giant cells destroy surrounding bone, producing the lytic lesions visible on imaging. Blocking RANKL with denosumab interrupts this recruitment, causes giant cell apoptosis, and promotes new bone formation within the lesion. This mechanism is described in a 2010 New England Journal of Medicine report.

Who Is a Candidate for Denosumab in GCTB?

NCCN guidelines for bone cancer identify denosumab as a systemic option in three clinical scenarios:

1. Unresectable GCTB (for example, sacral or spinal tumors where en bloc resection carries unacceptable neurological risk).
2. Surgically resectable GCTB where surgery would cause severe morbidity (joint sacrifice, amputation).
3. Recurrent or metastatic GCTB after prior surgery.

Neoadjuvant use before planned surgery has also been studied to reduce tumor vascularity and consolidate bone, potentially converting an intralesional procedure into a more favorable resection.

Clinical Evidence Supporting Denosumab in GCTB

The Phase II Amgen Study (Study 20062004)

The key evidence base is the Phase II open-label, multicenter trial published by Chawla et al. In The Lancet Oncology in 2013. This study enrolled 282 patients across three cohorts: recurrent or unresectable GCTB, newly diagnosed resectable GCTB, and a third cohort of patients from a prior pilot study. The primary publication is available at The Lancet Oncology.

Key results from that trial:

• In Cohort 1 (unresectable or recurrent GCTB, N=170), 86% of evaluable patients had no disease progression at 6 months, defined by modified RECIST criteria.
• In Cohort 2 (resectable GCTB patients who chose to undergo surgery, N=101), 74% of surgeons reported the surgery was either less morbid than anticipated or that the tumor was no longer resectable in a way requiring major procedures.
• Objective response rate (partial or complete response by RECIST 1.1) was achieved in 25 of 187 evaluable patients (13%), reflecting the difficulty of applying standard oncology response criteria to a primarily bone-contained lesion.

The trial was not randomized against surgery or placebo, which is the primary limitation cited when assigning a GRADE evidence level.

GRADE Evidence Level for GCTB

Applying the GRADE framework to denosumab in GCTB:

• Evidence level: Moderate. The Phase II trial was large and prospective but non-randomized, with no control arm. Outcomes were meaningful (disease stabilization, reduced surgical morbidity) but measured on surrogate endpoints rather than overall survival.
• Strength of recommendation: Strong in unresectable disease (few alternatives exist); Conditional in resectable disease where surgery remains the gold standard.

The absence of a randomized controlled trial is not a gap that is likely to be filled: GCTB is rare, surgery is the established standard for resectable lesions, and randomizing patients to surgery vs. No surgery with denosumab alone raises ethical difficulties.

Long-Term Follow-Up Data

A long-term follow-up analysis published in Bone (2019) examined outcomes in patients from the Phase II study who had received denosumab for a median of 13.4 months. Tumor recurrence after denosumab discontinuation was observed in approximately 54% of patients who had stopped treatment, underscoring the concern that denosumab suppresses rather than eradicates the tumor in many cases. This follow-up data is summarized in PubMed.

Dosing Protocol for Denosumab in Giant Cell Tumor of Bone

The dosing protocol for GCTB comes from the Xgeva prescribing information and the Phase II trial protocol, not from the Prolia label. Any clinician considering this therapy should use Xgeva 120 mg, not Prolia 60 mg.

Standard Dosing Schedule

| Timepoint | Dose | Route | |---|---|---| | Day 1 (Cycle 1) | 120 mg | SC injection | | Day 8 (Cycle 1) | 120 mg | SC injection (loading) | | Day 15 (Cycle 1) | 120 mg | SC injection (loading) | | Day 1 of each subsequent 4-week cycle | 120 mg | SC injection |

The three loading doses in the first month are designed to rapidly achieve target RANKL suppression. After Cycle 1, dosing reverts to a single 120 mg injection every 28 days.

Injection sites are the upper arm, upper thigh, or abdomen. The solution should be allowed to reach room temperature for approximately 15 to 30 minutes before administration. Do not shake the vial.

Duration of Treatment

Treatment duration in GCTB is not standardized. In the Phase II trial, patients received a median of 13 doses. In clinical practice, denosumab is typically continued until:

• Surgical resection becomes feasible (neoadjuvant intent), or
• Disease progression occurs on therapy, or
• Unacceptable toxicity develops.

Indefinite maintenance has been used in unresectable cases, but the high recurrence rate after stopping, combined with concerns about osteonecrosis of the jaw (ONJ) with prolonged use, makes indefinite therapy a decision requiring careful shared decision-making.

Pre-Treatment Requirements

Before the first dose and before each subsequent dose, the following must be confirmed or completed:

• Serum calcium must be within normal range. Denosumab can cause severe symptomatic hypocalcemia. The FDA label carries a black-box warning for hypocalcemia in patients with renal impairment.
• Calcium supplementation: at least 500 mg elemental calcium daily.
• Vitamin D supplementation: at least 400 IU daily.
• Dental examination before starting therapy is strongly recommended given ONJ risk. Invasive dental procedures should be avoided during treatment.
• Pregnancy status: denosumab is Pregnancy Category X equivalent under the current labeling framework. Women of reproductive age must use effective contraception during treatment and for at least 5 months after the last dose. Reproductive safety data are summarized in the FDA label.

Safety Profile and Monitoring

Most Common Adverse Effects in GCTB Trials

Data from the Phase II study and the broader Xgeva safety database identify the following adverse effects relevant to GCTB patients:

• Hypocalcemia: Occurred in 5% of patients in the Phase II study as a grade 3 or 4 event. Risk is highest in the first weeks of therapy and in patients with vitamin D deficiency at baseline. Hypocalcemia with denosumab is described in detail in multiple PubMed-indexed case series.
• Osteonecrosis of the jaw (ONJ): Cumulative incidence in the 120 mg Xgeva population across all indications is approximately 1.8% at 1 year and rises with treatment duration. Patients with active dental disease, smoking history, or corticosteroid use carry higher risk. ONJ incidence data from the combined Xgeva safety analysis are indexed on PubMed.
• Atypical femoral fracture: A rare but recognized complication with long-term RANKL inhibition. Patients should be counseled to report new thigh or groin pain.
• Rebound hypercalcemia: After denosumab discontinuation, rebound osteoclast activity can cause clinically significant hypercalcemia, particularly in pediatric or adolescent patients with high bone turnover. This can require bisphosphonate bridging therapy at the time of stopping denosumab. A case series describing rebound hypercalcemia is available via PubMed.

Monitoring Schedule During Treatment

| Parameter | Frequency | |---|---| | Serum calcium, phosphate, magnesium | Before each dose for the first 6 months, then every 3 months | | Renal function (eGFR) | Baseline, then every 6 months | | Dental assessment | Before starting; every 6 months during prolonged therapy | | Imaging (MRI or CT of tumor site) | Every 3 to 6 months to assess response |

Neoadjuvant Denosumab: Reducing Surgical Morbidity

One of the most clinically useful applications of denosumab in GCTB is the neoadjuvant setting, where the goal is not to replace surgery but to change the nature of the surgery required.

Evidence for Neoadjuvant Use

In Cohort 2 of the Amgen Phase II trial, 74% of surgeons reported a change in surgical approach after denosumab treatment. In a subset of patients with planned joint-sacrificing procedures, a number were able to undergo joint-sparing curettage instead after a course of denosumab-induced tumor consolidation. The Lancet Oncology Phase II publication details these outcomes.

A retrospective multicenter study published in JBJS examined 47 patients who received neoadjuvant denosumab before curettage. Local recurrence rates at 2 years were not statistically different from historical curettage-alone controls, though the study was underpowered for this comparison. JBJS data are indexed at PubMed.

Histological Changes That Matter Surgically

After 3 to 6 months of denosumab, pathological examination of resected specimens typically shows:

• Elimination of multinucleated giant cells (the RANKL-dependent osteoclast-like cells).
• Replacement of tumor stroma with woven bone and fibrous tissue.
• Reduced vascularity, which decreases intraoperative blood loss.

These changes can make intraoperative margins harder to interpret because the usual histological landmarks are absent. Surgeons and pathologists should communicate clearly before resection in a patient who has received neoadjuvant denosumab.

Pediatric and Adolescent Considerations

Denosumab's Xgeva indication for GCTB includes skeletally mature adolescents. In patients with open growth plates (Risser stage 0 to 2 or equivalent), denosumab is generally avoided because RANKL signaling is essential for normal endochondral ossification. Guidance on skeletal maturity assessment is discussed in pediatric orthopedic oncology literature indexed at PubMed.

For skeletally immature patients with unresectable GCTB, multidisciplinary discussion is required. Use in this population is off-label even relative to the Xgeva indication, and the risk of growth plate disruption must be weighed against the clinical necessity.

Denosumab After Recurrence Following Surgery

GCTB recurs locally in 15% to 50% of cases after intralesional curettage, depending on adjuvant technique (phenol, cement, cryotherapy). After recurrence, options include repeat curettage, wide resection, or systemic therapy with denosumab. Recurrence rates after curettage are reviewed in a meta-analysis indexed at PubMed.

Denosumab has produced responses in patients who have recurred after one or more prior surgeries. The Phase II trial enrolled 170 patients in Cohort 1 who were either unresectable at diagnosis or had recurred. The 86% 6-month non-progression rate described above applies to this mixed cohort. Patients with recurrent disease who had a second surgery after denosumab consolidation had a lower re-recurrence rate compared with historical re-operation data, though no prospective randomized data exist to confirm this comparison.

Practical Prescribing Summary: Prolia vs. Xgeva for GCTB

Clinicians sometimes ask whether Prolia can substitute for Xgeva in GCTB, either due to formulary restrictions or cost considerations. The answer is no, for two reasons:

1. Dose: Prolia delivers 60 mg every 6 months. Xgeva delivers 120 mg every 4 weeks with loading doses. The pharmacokinetic exposure is not equivalent, and no pharmacokinetic bridging data support using Prolia dosing for tumor control.
2. FDA indication: Xgeva carries the GCTB indication. Prolia does not. Using Prolia for GCTB is off-label use of the wrong formulation, not simply off-label use of denosumab.

If a patient has a formulary or insurance situation where Prolia is approved but Xgeva is not, the prescriber must document the medical necessity for the higher-dose formulation and pursue a prior authorization or appeal. Substituting Prolia at its approved osteoporosis dose would not be clinically equivalent and should not be done.

As the Xgeva prescribing information states directly: "Prolia and Xgeva contain the same active ingredient (denosumab) and patients receiving Prolia should not receive Xgeva concurrently." They are not interchangeable in dose or indication. This statement appears in the current FDA label.

Summary of Evidence and Clinical Position

Denosumab at 120 mg SC every 4 weeks (Xgeva formulation) is an FDA-approved treatment for giant cell tumor of bone in adults and skeletally mature adolescents, supported by a Phase II trial in which 86% of evaluable patients showed no disease progression at 6 months. The Prolia 60 mg formulation is not appropriate for this indication. Clinicians should use the Xgeva label for dosing guidance, mandate calcium and vitamin D supplementation, obtain a dental assessment before starting, monitor serum calcium before each dose, and counsel patients about the approximately 54% recurrence rate after stopping therapy.